Phase II study of antineoplastons A10 and AS2-1 in patients with metastatic or incurable neuroendocrine tumors
Latest Information Update: 08 Jul 2013
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 12 Dec 2006 Status change
- 12 Aug 2005 New trial record.